Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Clinical trial NCT02227251 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02227251
- Sponsor
- Karyopharm Therapeutics Inc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-01
- Primary completion
- 2026-12-01
- Enrollment
- 244
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.